The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Objective: To assess the effect of the metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM) AZD8529 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs)…Response to Levodopa in Parkinson´s Disease Over Time. A 4-year Follow-up Study.
Objective: The aim of the present study was to analyze the response to levodopa in Parkinson´s disease (PD) patients with motor fluctuations followed up for…Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson’s disease in a marmoset monkey model
Objective: To demonstrate the effects of an oral, anti-inflammatory agent, NE3107, on motor activity, levodopa-induced dyskinesia (LID) induction, and neuron survival in a marmoset model…Analysis of levodopa use in patients with Parkinson’s Disease during pregnancy: a systematic review of the last twenty years
Objective: To evaluate the role of oral levodopa in patients with Parkinson’s disease (PD) during pregnancy, using the available literature, in order to determine the…Pharmacological combinations in early stages of Parkinson’s disease and association with motor complications
Objective: To describe the different combinations of dopaminergic drugs at the early stage of Parkinson’s disease (PD) in a real-life cohort, and to determine their…VALIdation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson’s disease (VALIDATE)
Objective: To externally validate the Dutch Device-Aided Therapy Screening tool (D-DATS) and to compare it with the 5-2-1 criteria. Background: Timely identification of patients with…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…Prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population
Objective: To know the prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population Background: Parkinson’s disease (PD) is a neurodegenerative disease which…Asymptomatic Gaucher disease presented as Parkinsonism in 61 years old patient.
Objective: Gaucher disease is an inherited disease caused by a mutation in the glucocerebrosidase gene, causing visceral, hematologic, and skeletal involvement. [1] [2] We report…Response of extraocular movements in parkinson’s disease to levodopa: an electrooculographic perspective
Objective: To determine the response of latencies and amplitudes of saccadic movements to Levodopa in idiopathic Parkinson’s Disease. Background: Neurodegeneration in Parkinson’s Disease (PD) increases…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 57
- Next Page »